Therapeutic Effects of a Novel Fusion of Alt-803, an Il-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2b8t2m) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (Bl)

Document Type

Abstract

Publication Date

6-2018

Journal Title

Pediatric Blood & Cancer

Department

Pediatrics

Second Department

Epidemiology and Community Health

This document is currently not available here.

Share

COinS